生存率 来自妙佑医疗国际员工 原发纵隔大 B 细胞淋巴瘤（PMBCL）的生存几率因人而异。影响因素包括整体健康状况、癌症分期、正在接受的治疗以及您对治疗的反应。 PMBCL 存在治疗后再次发生（复发）的风险。大多数复发发生在治疗后的头两年内。 原发纵隔大 B 细胞淋巴瘤的总体五年生存率通常超过 80%。这意味着超过 80% 确诊 PMBCL 的患者在确诊五年后仍然存活。 预后癌症预后反映癌症可成功治疗的可能性。医护团队可以根据您的原发纵隔大 B 细胞淋巴瘤（PMBCL）分期和您的整体健康状况大致判断预后情况。 如果您想了解治疗后的情况，请与医护团队讨论您的预后。医护团队的成员可以解释在评估您的预后时会考虑哪些因素。 申请预约 分期医生与科室 May 20, 2026 Share on: FacebookTwitterWeChatWeChatCloseWeibo Living with 原发纵隔大 B 细胞淋巴瘤? Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community. Blood Cancers & Disorders Discussions AML successful treatment 102 Replies Tue, Jul 14, 2026 chevron-right Essential Thrombocythemia: Looking for information and support 676 Replies Mon, Jul 13, 2026 chevron-right What are your experiences with lenalidomide (Revlimid) for MDS? 32 Replies Sun, Jul 12, 2026 chevron-right See more discussions 显示参考文献 B-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480. Accessed Dec. 17, 2025. Aster JC, et al. Primary mediastinal large B-cell lymphoma. https://www.uptodate.com/contents/search. Accessed Dec. 17, 2025. Brown JR, et al. Pathobiology of diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma. https://www.uptodate.com/contents/search. Accessed Dec. 17, 2025. Hsi ED, et al., eds. Diffuse aggressive B-cell lymphomas. In: Hematopathology: Foundations in Diagnostic Pathology. 4th ed. Elsevier; 2026. https://www.clinicalkey.com. Accessed Dec. 17, 2025. Mediastinum. Dorland's Medical Dictionary Online. https://www.dorlandsonline.com. Accessed Dec. 17, 2025. Paulson CL. Allscripts EPSi. Mayo Clinic. July 15, 2025. 相关 相关医疗程序 CAR T 细胞疗法 CT 扫描 化疗 放射疗法 正电子发射体层成像（PET）扫描 癌症生物疗法 骨髓移植 显示更多相关医疗程序 原发纵隔大 B 细胞淋巴瘤症状与病因诊断与治疗分期生存率医生与科室在 Mayo Clinic 治疗 CON-20592493 疾病与状况 原发纵隔大 B 细胞淋巴瘤